within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M05B_DrugsAffectingBoneStructureAndMineralization.M05BA08_ZoledronicAcid;

model ZoledronicAcid
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.0277777777777777e-06,
    adminDuration = 600,
    adminMass = 4 / 1000000,
    adminCount = 1,
    Vd = 0.0065,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0027,
    k12 = 1.8333333333333333e-07,
    k21 = 1.8333333333333333e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>ZoledronicAcid</td></tr><tr><td>ATC code:</td><td>M05BA08</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>4</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>6.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.7</td><td>l/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Zoledronic acid is a third-generation bisphosphonate used primarily for the treatment of osteoporosis, Paget’s disease of bone, and to prevent skeletal-related events in patients with cancers such as multiple myeloma and bone metastases from solid tumors. It is approved and widely used clinically for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters derived from adult cancer patients (solid tumors, multiple myeloma) receiving single intravenous doses.</p><h4>References</h4><ol><li><p>Miller, PD (2011). The kidney and bisphosphonates. <i>Bone</i> 49(1) 77–81. DOI:<a href=\"https://doi.org/10.1016/j.bone.2010.12.024\">10.1016/j.bone.2010.12.024</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21232648/\">https://pubmed.ncbi.nlm.nih.gov/21232648</a></p></li><li><p>Shiraki, M, et al., &amp; Nakamura, T (2017). Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis. <i>Journal of bone and mineral metabolism</i> 35(6) 675–684. DOI:<a href=\"https://doi.org/10.1007/s00774-016-0806-3\">10.1007/s00774-016-0806-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28000034/\">https://pubmed.ncbi.nlm.nih.gov/28000034</a></p></li><li><p>Lyseng-Williamson, KA (2008). Zoledronic acid: a review of its use in breast cancer. <i>Drugs</i> 68(18) 2661–2682. DOI:<a href=\"https://doi.org/10.2165/0003495-200868180-00010\">10.2165/0003495-200868180-00010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19093706/\">https://pubmed.ncbi.nlm.nih.gov/19093706</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M05BA08 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end ZoledronicAcid;
